As of September 30, 2024, the Company had cash, cash equivalents and marketable securities totaling $203.7 million, which provides projected cash runway into 2026.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics initiated with an Outperform at Oppenheimer
- Larimar Therapeutics initiated with an Outperform at Wedbush
- Wedbush bullish on Larimar Therapeutics, initiates with an Outperform
- Larimar Therapeutics initiated with a Buy at H.C. Wainwright
- Larimar Therapeutics initiated with a Buy at JonesResearch